Breaking News, Financial News

Financial Report: AbbVie

HUMIRA sales up 11% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie 4Q Revenues: $5.5 billion (+7%)  4Q Loss: $810 million (earnings were $1.1 billion 4Q13) FY Revenues: $20.0 billion (+6%) FY Earnings: $1.8 billion (earnings were $4.1 billion FY13) Comments: Growth in the quarter was driven primarily by HUMIRA sales, up 11% to $3.4 billion. Creon sales were $151 million, up 31%. Dyslipidemia sales were $104 million, up 14%. Synagis sales were down 5% to 298 million in the quarter. AndroGel sales declined 20% to $230 million. Earnings were impacted t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters